Beneficial drugs for liver diseases

被引:115
作者
Muriel, Pablo [1 ]
Rivera-Espinoza, Yadira [2 ]
机构
[1] Cinvestav IPN, Dept Farmacol, Mexico City 07000, DF, Mexico
[2] Inst Politecn Nacl, Escuela Nacl Ciencias Biol, Dept Grad & Invest Alimentos, Mexico City 11340, DF, Mexico
关键词
colchicine; curcumin; interferons; nitric oxide; resveratrol; silymarin; S-adenosyl-L-methionine; thalidomide; liver damage;
D O I
10.1002/jat.1310
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Liver diseases are a major problem of worldwide proportions. However, the number of drugs actually used successfully in humans is very small. In this review some of the most promising/studied drugs utilized for liver diseases were chosen and analysed critically from the basic to the clinical point of view. Antiviral agents are not discussed because excellent reviews have appeared on this topic. The compounds/preparations described herein are, alphabetically: colchicine, corticosteroids, curcumin, glycyrrhizin, interferons (for their antifibrotic properties), Liv 52, nitric oxide, resveratrol, silymarin, sulfoadenosyltnethionine, and thalidomide. Colchicine and corticosteroids have been studied extensively in animals and humans; most clinical studies suggest that these compounds are not useful in the treatment of liver diseases. Glycyrrhizin is an herbal medicine with several components that has interesting hepatoprotective properties in patients with subacute liver failure but deserves more prospective controlled trials. Interferon has shown interesting antifibrotic properties in animals and humans; prospective studies on their antifibrotic/fibrolytic activity are required. Curcumin, resveratrol and thalidomide are very attractive newly discovered protective and curative compounds on experimental hepatic diseases. Their mechanism of action is associated with the ability to down-regulate NF-kappa B and to decrease pronecrotic and profibrotic cytokines. Unfortunately, clinical studies are lacking. Sulfoadenosylmethionine and silymarin are also promising drugs utilized mainly in cholestasis but the benefits can be expanded if more controlled trials are performed. The future is to carry out controlled prospective double-blind multicenter studies with the newly discovered drugs with proven beneficial effects on animals. Fundamental hepatobiology should also be encouraged. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 140 条
  • [51] S-adenosylmethionine synthesis: Molecular mechanisms and clinical implications
    Mato, JM
    Alvarez, L
    Ortiz, P
    Pajares, MA
    [J]. PHARMACOLOGY & THERAPEUTICS, 1997, 73 (03) : 265 - 280
  • [52] S-adenosylmethionine in alcoholic liver cirrhosis:: A randomized, placebo-controlled, double-blind, multicenter clinical trial
    Mato, JM
    Cámara, J
    de Paz, JF
    Caballería, L
    Coll, S
    Caballero, A
    García-Buey, L
    Beltrán, J
    Benita, V
    Caballería, J
    Solà, R
    Moreno-Otero, R
    Barrao, F
    Martín-Duce, A
    Correa, JA
    Parés, A
    Barrao, E
    García-Magaz, I
    Puerta, JL
    Moreno, J
    Boissard, G
    Ortiz, P
    Rodés, J
    [J]. JOURNAL OF HEPATOLOGY, 1999, 30 (06) : 1081 - 1089
  • [53] S-adenosylmethionine: a control switch that regulates liver function
    Mato, JM
    Corrales, FJ
    Lu, SC
    Avila, MA
    [J]. FASEB JOURNAL, 2002, 16 (01) : 15 - 26
  • [54] Role of S-adenosyl-L-methionine in liver health and injury
    Mato, Jose M.
    Lu, Shelly C.
    [J]. HEPATOLOGY, 2007, 45 (05) : 1306 - 1312
  • [55] Miller AL., 1996, ALTERN MED REV, V1, P103
  • [56] Miller MT, 1999, TERATOLOGY, V60, P306, DOI 10.1002/(SICI)1096-9926(199911)60:5<306::AID-TERA11>3.0.CO
  • [57] 2-Y
  • [58] Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin
    Miyaji, C
    Miyakawa, R
    Watanabe, H
    Kawamura, H
    Abo, T
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2002, 2 (08) : 1079 - 1086
  • [59] THALIDOMIDE EXERTS ITS INHIBITORY-ACTION ON TUMOR-NECROSIS-FACTOR-ALPHA BY ENHANCING MESSENGER-RNA DEGRADATION
    MOREIRA, AL
    SAMPAIO, EP
    ZMUIDZINAS, A
    FRINDT, P
    SMITH, KA
    KAPLAN, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (06) : 1675 - 1680
  • [60] Inducible nitric oxide synthase is not essential for the development of fibrosis and liver damage induced by CCl4 in mice
    Moreno, Mario G.
    Muriel, Pablo
    [J]. JOURNAL OF APPLIED TOXICOLOGY, 2006, 26 (04) : 326 - 332